Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.
Navigating these stocks isn’t easy, which is why StockStory helps you find Comfort In Chaos. That said, here is one volatile stock that could reward patient investors and two that could just as easily collapse.
Two Stocks to Sell:
10x Genomics (TXG)
Rolling One-Year Beta: 1.60
Founded in 2012 by scientists seeking to overcome limitations in traditional biological research methods, 10x Genomics (NASDAQ: TXG) develops instruments, consumables, and software that enable researchers to analyze biological systems at single-cell resolution and spatial context.
Why Do We Think Twice About TXG?
- Sales trends were unexciting over the last two years as its 6.5% annual growth was below the typical healthcare company
- Cash-burning tendencies make us wonder if it can sustainably generate shareholder value
- Push for growth has led to negative returns on capital, signaling value destruction
10x Genomics’s stock price of $13.79 implies a valuation ratio of 2.9x forward price-to-sales. To fully understand why you should be careful with TXG, check out our full research report (it’s free).
Synovus Financial (SNV)
Rolling One-Year Beta: 1.62
Tracing its roots back to 1888 when a worker accidentally dropped a textile mill payroll into the dust, prompting the need for better banking, Synovus Financial (NYSE: SNV) is a regional financial services company that provides commercial and consumer banking, wealth management, and specialized lending services across five southeastern states.
Why Are We Cautious About SNV?
- 4% annual net interest income growth over the last five years was slower than its banking peers
- Projected net interest income growth of 5.6% for the next 12 months suggests sluggish demand
- Net interest margin of 3.2% reflects its high servicing and capital costs
Synovus Financial is trading at $50 per share, or 1.3x forward P/B. Read our free research report to see why you should think twice about including SNV in your portfolio.
One Stock to Buy:
Amalgamated Financial (AMAL)
Rolling One-Year Beta: 1.08
Founded in 1923 by labor unions seeking a financial institution aligned with worker values, Amalgamated Financial (NASDAQGM:AMAL) operates a values-oriented bank that provides commercial banking, trust services, and investment management to socially responsible organizations and individuals.
Why Is AMAL a Top Pick?
- 10% annual net interest income growth over the last five years surpassed the sector average as its loans resonated with borrowers
- Additional sales over the last two years increased its profitability as the 8% annual growth in its earnings per share outpaced its revenue
- Annual tangible book value per share growth of 20.4% over the last two years was superb and indicates its capital strength increased during this cycle
At $29.73 per share, Amalgamated Financial trades at 1.1x forward P/B. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.
High-Quality Stocks for All Market Conditions
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
